N
NOMAD POWER SOLUTIONS, INC.
NMADCIK 0001335105NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-6.08M
Total Assets
$12.73M
Equity
$9.66M
Shares Out
12.38M
Op. Cash Flow
$-3.07M
Business
Nomad Power Solutions, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies centered on protein phosphatase 2A inhibitors, with its lead compound LB-100 in clinical trials for ovarian clear cell carcinoma, metastatic colon cancer, and soft tissue sarcoma. The company also owns a majority stake in Liora Technologies Europe Ltd., which is developing the LiGHT System, an electronically controlled proton linear accelerator for cancer radiation therapy. The company operates through clinical collaborations with major cancer centers and maintains a pipeline of combination therapies pairing LB-100 with checkpoint inhibitors and chemotherapy agents.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues, net | — | — | — | — | — | |
| General and administrative costs (includes $1,388,322 and $418,422 of stock-based compensation, respectively) | 5 | 3 | 4 | 3 | 3 | |
| Research and development costs | 254,919 | 726,232 | 898,100 | 1 | 2 | |
| Total costs and expenses | 5 | 4 | 5 | 6 | 7 | |
| Loss from operations | −5 | −4 | −5 | −6 | −7 | |
| Interest Income | 7,388 | 7,048 | 17,486 | 11,195 | 626 | |
| Interest Expense | −9,158 | −16,821 | −16,233 | −8,875 | −7,414 | |
| Realized loss on digital assets | −904,394 | — | — | — | — | |
| Foreign currency gain (loss) | 525 | −3,403 | — | — | — | |
| Other income | 3,740 | — | — | — | — | |
| Net loss | −6 | −4 | — | — | — | |
| Series B Convertible Preferred Stock 8% cumulative dividend | −69,073 | — | — | — | — | |
| Non-controlling interest | — | — | — | — | — | |
| Net loss attributable to common stockholders | −6 | −4 | −5 | −6 | −7 | |
| Earnings Per Share, Diluted | −1.26 | −1.59 | −2.66 | −3.99 | — | |
| Weighted Average Number of Shares Outstanding, Diluted | 5 | 2 | 2 | 2 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-11-30 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash | 5 | — | 1 | 4 | — | |
| Prepaid insurance | 26,682 | — | 20,898 | 17,116 | 49,224 | |
| Other prepaid expenses | 44,825 | — | 85,653 | 10,000 | 11,350 | |
| Total current assets | 5 | — | 1 | 4 | 6 | |
| LiGHT proton therapy system equipment | 7 | — | — | — | — | |
| Right-of-use lease assets | 972,682 | 1 | — | — | — | |
| Total assets | 13 | — | 1 | 4 | 6 | |
| Accounts payable and accrued expenses, including $125,959 and $27,500 to related parties at December 31, 2025 and December 31, 2024, respectively | 436,482 | — | 83,206 | 156,758 | 230,734 | |
| Research and development contract liabilities | 232,138 | — | 235,078 | 157,100 | 165,022 | |
| Operating lease obligations, current | 595,418 | — | — | — | — | |
| Series B Convertible Preferred Stock 8% cumulative dividend payable | 69,073 | — | — | — | — | |
| Total current liabilities | 1 | — | 318,284 | 313,858 | 395,756 | |
| Operating lease obligations, long-term | 438,959 | — | — | — | — | |
| Total liabilities | 2 | — | 318,284 | — | — | |
| Commitments and Contingencies | — | — | — | — | — | |
| Common stock, $0.0001 par value authorized 100,000,000 shares; issued and outstanding 8,790,102 and 2,249,290 shares at December 31, 2025 and 2024, respectively | 879 | — | 225 | 225 | 166 | |
| Additional paid-in capital | 66 | — | 49 | 49 | 45 | |
| Accumulated deficit | −58 | — | −52 | −48 | −43 | |
| Total Lixte Biotechnology stockholders equity | 10 | — | 827,219 | 4 | 5 | |
| Non-controlling interest | 1 | — | — | — | — | |
| Total stockholders equity | 11 | — | 827,219 | 4 | — | |
| Total liabilities and stockholders equity | 13 | — | 1 | 4 | 6 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Non-cash lease expense for right-of-use asset | 61,695 | — | — | — | — | |
| Common stock issued for services | 171,611 | — | — | — | — | |
| Advances on research and development contract services | — | 78,016 | 69,001 | 3,224 | −73,343 | |
| Prepaid insurance | −5,784 | −3,782 | 32,108 | 59,805 | −41,718 | |
| Other prepaid expenses | 40,828 | −75,653 | 1,350 | 1,350 | — | |
| Accounts payable and accrued expenses | 380,776 | −73,552 | −73,976 | 2,318 | 35,673 | |
| Research and development contract liabilities | −2,940 | 77,978 | −7,922 | 88,061 | 61,196 | |
| Net cash used in operating activities | −3 | −3 | −4 | −5 | −4 | |
| Purchase of digital assets | −3 | — | — | — | — | |
| Cash paid for Liora investment | −440,000 | — | — | — | — | |
| Capitalized transaction costs | −95,102 | — | — | — | — | |
| Net cash used in investing activities | −3 | — | — | — | — | |
| Proceeds from sale of securities in registered direct offerings, net of offering costs | 6 | — | 3 | 5 | 4 | |
| Proceeds from sale of securities in registered private placement, net of offering costs | 4 | — | — | — | — | |
| Exercise of common stock warrants | 45,801 | — | 41 | — | 17,100 | |
| Net cash provided by financing activities | 10 | — | 3 | 5 | 4 | |
| NET CHANGE IN CASH | 4 | −3 | — | — | — | |
| Cash paid for interest | 9,158 | 16,821 | 16,233 | 8,875 | 7,414 | |
| Cash paid for income taxes | — | — | — | — | — | |
| Options issued to settle accrued Board fees | 27,500 | — | — | — | — | |
| Exercise of placement agent warrants on a cashless basis | 22 | — | — | — | — | |
| Exercise of pre-funded warrants | 306 | — | — | — | — | |
| Conversion of Series A Convertible Preferred Stock into common stock | 4 | — | — | — | — | |
| Conversion of Series B Convertible Preferred Stock into common stock | 821,790 | — | — | — | — | |
| Accrual of Series B Convertible Preferred Stock 8% cumulative dividend | 69,073 | — | — | — | — | |
| Dividend payable settled in shares | 20,075 | — | — | — | — | |
| Digital assets transferred as consideration for acquisition of Liora (non-cash investing) FV at transfer | 2 | — | — | — | — | |
| Common stock issued for acquisition of Liora | 3 | — | — | — | — | |
| Right-of use asset and lease liability - operating lease (UKRI Daresbury) | 1 | — | — | — | — | |
| Non-controlling interest | 1 | — | — | — | — | |
| Accrual of deferred offering costs | — | 6,928 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is NOMAD POWER SOLUTIONS, INC.'s CIK number?
NOMAD POWER SOLUTIONS, INC.'s SEC CIK number is 0001335105 (1335105). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find NOMAD POWER SOLUTIONS, INC.'s SEC filings?
All of NOMAD POWER SOLUTIONS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.